Gregg L. Katz

Mr. Katz’s transactional experience includes representing: 

Public Offerings - Issuer

• Moderna, a clinical-stage biotechnology company pioneering mRNA therapeutics and vaccines, in its $604 million initial public offering on NASDAQ and in its $575 million and $1.3 billion follow-on offerings
• bluebird bio, a biotechnology company developing gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, in its $116 million initial public offering on NASDAQ and in eight follow-on public offerings totaling $3.5 billion
• Alnylam Pharmaceuticals, a leading RNAi therapeutics company, in four follow-on public offerings totaling $2.9 billion
• Aquaventure Holdings, a multinational provider of water-as-a-service solutions, in its $135 million initial public offering on NYSE and its $80 million follow-on offering
• Eloqua, a provider of on-demand revenue performance management software solutions, in its $106 million initial public offering on NASDAQ
• Omthera Pharmaceuticals, a pharmaceutical company focused on therapies for abnormalities in blood lipids and the treatment of cardiovascular disease, in its $64 million initial public offering on NASDAQ

Public Offerings - Underwriter

• Goldman Sachs and Morgan Stanley in the $300 million initial public offering of Blue Apron on NYSE
• Goldman Sachs and Credit Suisse in the $113 million initial public offering of Alarm.com on NASDAQ
• Goldman Sachs and Deutsche Bank in the $235 million and $344 million follow-on public offerings of CyberArk Software
• J.P. Morgan and Deutsche Bank in the $99 million initial public offering of CyberArk Software on NASDAQ 
• Goldman Sachs and Credit Suisse in the $133 million initial public offering of 2U on NASDAQ and in three follow-on offerings totaling $688 million
• Stifel in the $57 million initial public offering of SPS Commerce on NASDAQ and in four follow-on offerings totaling $172 million

Private Financings

• Toast, a restaurant management platform, in its Series B, Series C, Series D, Series E and Series F financings
• Salsify, a product content management platform for distributed commerce, in its Series A, Series B, Series C and Series D financings
• Circle Internet Financial, a digital currency company, in its Series A, Series B, Series C, Series D and Series E financings
• Alnylam Pharmaceuticals, a leading RNAi therapeutics company, in a $700 million equity financing closed in connection with Alnylam’s collaboration with Sanofi Genzyme, a $400 million equity financing closed in connection with Alnylam’s collaboration with Regeneron, and a $100 million equity financing closed in connection with Alnylam’s collaboration with Blackstone
• Carrick Therapeutics, a European oncology company, in its initial funding round
• Wellframe, a market leader in Digital Health Management solutions, in its Series C financing
• Genomics Medicine Ireland, an Irish genomics research company, in its Series A financing
• TellusLabs, a leader in the use of satellite imaging for developing agricultural insights, in its seed financing
• Sansoro Health, a pioneer in data integration for health care, in its Series B financing
• OM1, a leading health outcomes and technology company, in its Series B and Series C financings
• Innophase, an innovative semiconductor company, in its financing rounds
• Infinio Systems, a leader in storage acceleration for virtualized data centers, in its financing rounds and subsequent sale
• Bedford Funding in its Series C and Series D investments in Voalte and Series D investment in MDLIVE

Mergers & Acquisitions

• Circle Internet Financial, a digital currency company, in the acquisition and subsequent spin-out of the Poloniex cryptocurrency trading platform and in the acquisition of SeedInvest
• Teva Pharmaceutical Industries, a leading global pharmaceutical company, in the sale of its specialty women’s global health business
• iRobot Corporation, a leading global consumer robot company in its acquisitions of Robopolis SAS, Evolution Robotics and Root Robotics and in the sale of its Defense & Security business to Arlington Capital Partners
• Genomics Medicine Ireland, an Irish genomics research company, in its sale to WuXi NextCODE
• Sansoro Health, a pioneer in data integration for health care, in its acquisition of Datica Health
• Cobalt Biomedicine, a biotechnology company, in its sale to Sana Biotechnology
• TellusLabs, a leader in the use of satellite imaging for developing agricultural insights, in its sale to Indigo Agriculture
• RedBrick Health, a health engagement and behavior-based technology company, in its sale to Marlin Equity Partners
• Code42 Software, a leader in cloud-based endpoint data protection and recovery, in the sale of its consumer business to Carbonite
• Plex Systems, a leader in cloud ERP for manufacturing, in its acquisitions of DemandCaster and DATTUS
• Epidemico, an informatics company providing early insights, continuous monitoring and consumer engagement for varied aspects of population health, in its sale to Booz Allen Hamilton
• bluebird bio, a biotechnology company developing gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, in its acquisition of Precision Genome Engineering
• Eloqua, a leading provider of on-demand revenue performance management software solutions, in its sale to Oracle Corporation
• Endeca Technologies, a provider of unstructured data management, web commerce and business intelligence solutions, in its sale to Oracle Corporation
• Attend, an event software company, in its sale to Event Farm
• WaveMark, a provider of real-time healthcare supply chain solutions, in its sale to Cardinal Health